Jpmorgan Chase & CO Erasca, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Erasca, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,415,244 shares of ERAS stock, worth $3.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,415,244

Previous 1,474,585 4.02%

Holding current value

$3.4 Million

Previous $3.7 Million 47.64%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.28 - $2.75 $75,956 - $163,187	-59,341 Reduced 4.02%	1,415,244 $1.94 Million
Q4 2024 Feb 12, 2025	SELL	$2.44 - $3.23 $1.34 Million - $1.78 Million	-549,929 Reduced 27.16%	1,474,585 $3.7 Million
Q3 2024 Dec 26, 2024	SELL	$2.17 - $3.28 $28,427 - $42,968	-13,100 Reduced 0.64%	2,024,514 $5.53 Million
Q3 2024 Nov 08, 2024	SELL	$2.17 - $3.28 $28,427 - $42,968	-13,100 Reduced 0.64%	2,024,514 $5.53 Million
Q2 2024 Dec 26, 2024	BUY	$1.79 - $2.63 $23,449 - $34,453	13,100 Added 0.65%	2,037,614 $4.81 Million
Q2 2024 Aug 12, 2024	BUY	$1.79 - $2.63 $3.53 Million - $5.18 Million	1,971,460 Added 2980.11%	2,037,614 $4.81 Million
Q1 2024 Dec 26, 2024	SELL	$1.67 - $2.55 $3.27 Million - $4.99 Million	-1,958,360 Reduced 96.73%	66,154 $136,000
Q1 2024 May 10, 2024	SELL	$1.67 - $2.55 $34,537 - $52,736	-20,681 Reduced 23.82%	66,154 $136,000
Q4 2023 Dec 26, 2024	SELL	$1.67 - $2.49 $3.24 Million - $4.82 Million	-1,937,679 Reduced 95.71%	86,835 $184,000
Q4 2023 Feb 12, 2024	BUY	$1.67 - $2.49 $7,892 - $11,767	4,726 Added 5.76%	86,835 $184,000
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $28,765 - $42,491	14,602 Added 21.63%	82,109 $161,000
Q2 2023 Aug 11, 2023	BUY	$2.57 - $3.3 $30,256 - $38,850	11,773 Added 21.12%	67,507 $186,000
Q1 2023 May 18, 2023	BUY	$2.74 - $4.44 $151,702 - $245,825	55,366 Added 15045.11%	55,734 $167,000
Q1 2023 May 11, 2023	SELL	$2.74 - $4.44 $390,510 - $632,797	-142,522 Reduced 99.74%	368 $1,000
Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $385,281 - $848,807	99,044 Added 225.89%	142,890 $616,000
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $20,509 - $37,636	3,524 Added 8.74%	43,846 $341,000
Q2 2022 Aug 11, 2022	SELL	$4.58 - $8.72 $45,305 - $86,258	-9,892 Reduced 19.7%	40,322 $225,000
Q1 2022 May 11, 2022	BUY	$8.6 - $15.48 $227,478 - $409,461	26,451 Added 111.31%	50,214 $432,000
Q4 2021 Feb 10, 2022	BUY	$12.51 - $22.75 $201,998 - $367,344	16,147 Added 212.01%	23,763 $371,000
Q3 2021 Nov 12, 2021	BUY	$17.43 - $24.34 $132,746 - $185,373	7,616 New	7,616 $162,000

Others Institutions Holding ERAS

# of Institutions

150

Shares Held

216M

Call Options Held

258K

Put Options Held

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $293M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Erasca, Inc. Transaction History